KRAS and lung carcinoma: The results showed that the combination treatment of MA and osimertinib decreased the proliferation of KRAS-mutated lung cancer cells of A549 and H157 compared to the osimertinib treatment group at a low dose (1 μM) (Figure 6C; Supplementary Figure S6A).